RecruitingNot ApplicableNCT07393958
Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.
Experimental Study of Quality of Life in Patients With Endometriosis and Pelvic Pain Treated With Doliral Dietary Supplementation Versus Placebo.
Sponsor
Arafarma Group, S.A.
Enrollment
60 participants
Start Date
Feb 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria5
- Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.
- Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound.
- Presence of pelvic pain (VAS > 4) during the last three months.
- No indication for surgical intervention at the time of inclusion in the study.
- Patients who are able to provide informed consent.
Exclusion Criteria7
- Patients under 18 years of age.
- Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
- Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
- Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.
- Patients with known allergy or hypersensitivity to Doliral®.
- Pregnant or breastfeeding patients.
- Patients on sick leave: > 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTFood supplement (T1675)
Doliral is the food supplement, which is the investigational product at this study.
OTHERPlacebo
Placebo is the control treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07393958